{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T22:54:29Z","timestamp":1776293669774,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-89833"],"award-info":[{"award-number":["MOP-89833"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12951-016-0200-2","type":"journal-article","created":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T21:23:06Z","timestamp":1465507386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine"],"prefix":"10.1186","volume":"14","author":[{"given":"Gervais","family":"Rioux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Carignan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maril\u00e8ne","family":"Bolduc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-\u00c8ve Lalibert\u00e9","family":"Gagn\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Savard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-1638","authenticated-orcid":false,"given":"Denis","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,10]]},"reference":[{"key":"200_CR1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","volume":"12","author":"MT Osterholm","year":"2012","unstructured":"Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:36\u201344.","journal-title":"Lancet Infect Dis"},{"key":"200_CR2","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.vaccine.2005.08.105","volume":"24","author":"K Goodwin","year":"2006","unstructured":"Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24:1159\u201369.","journal-title":"Vaccine"},{"key":"200_CR3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coi.2014.03.008","volume":"29","author":"K Haq","year":"2014","unstructured":"Haq K, McElhaney JE. Immunosenescence: influenza vaccination and the elderly. CurrOpin Immunol. 2014;29:38\u201342.","journal-title":"CurrOpin Immunol."},{"key":"200_CR4","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","volume":"19","author":"SG Reed","year":"2013","unstructured":"Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19:1597\u2013608.","journal-title":"Nat Med"},{"key":"200_CR5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.drudis.2009.02.009","volume":"14","author":"DT O\u2019Hagan","year":"2009","unstructured":"O\u2019Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant\u2014\u201dthe long and winding road.\u201d. Drug Discov Today. 2009;14:541\u201351.","journal-title":"Drug Discov Today"},{"key":"200_CR6","doi-asserted-by":"crossref","unstructured":"Gar\u00e7on N, Hem S, Friede M. Chapter 5\u2014evolution of adjuvants across the centuries. In: Vaccines. 6th ed. London: W.B. Saunders; 2013: 58\u201370.","DOI":"10.1016\/B978-1-4557-0090-5.00020-3"},{"key":"200_CR7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33:492\u2013503.","journal-title":"Immunity"},{"key":"200_CR8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.coi.2012.03.008","volume":"24","author":"CR Alving","year":"2012","unstructured":"Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Curr Opin Immunol. 2012;24:310\u20135.","journal-title":"Curr Opin Immunol"},{"key":"200_CR9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nsmb.2331","volume":"19","author":"C Shu","year":"2012","unstructured":"Shu C, Yi G, Watts T, Kao CC, Li P. Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system. Nat Struct Mol Biol. 2012;19:722\u20134.","journal-title":"Nat Struct Mol Biol"},{"key":"200_CR10","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","volume":"29","author":"F Steinhagen","year":"2011","unstructured":"Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine. 2011;29:3341\u201355.","journal-title":"Vaccine"},{"key":"200_CR11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","volume":"5","author":"A Iwasaki","year":"2004","unstructured":"Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5:987\u201395.","journal-title":"Nat Immunol"},{"key":"200_CR12","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/bjc.1996.569","volume":"74","author":"P Savage","year":"1996","unstructured":"Savage P, Horton V, Moore J, Owens M, Witt P, Gore ME. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer. 1996;74:1482.","journal-title":"Br J Cancer."},{"key":"200_CR13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1586\/14760584.2013.811208","volume":"12","author":"JP Vasilakos","year":"2013","unstructured":"Vasilakos JP, Tomai MA. The use of Toll-like receptor 7\/8 agonists as vaccine adjuvants. Expert Rev Vaccines. 2013;12:809\u201319.","journal-title":"Expert Rev Vaccines"},{"key":"200_CR14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1742-4658.2005.05033.x","volume":"273","author":"M-H Tremblay","year":"2006","unstructured":"Tremblay M-H, Majeau N, Gagn\u00e9 MEL, Lecours K, Morin H, Duvignaud J, Bolduc M, Chouinard N, Par\u00e9 C, Gagn\u00e9 S, Leclerc D. Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein. FEBS J. 2006;273:14\u201325.","journal-title":"FEBS J"},{"key":"200_CR15","doi-asserted-by":"crossref","first-page":"e31925","DOI":"10.1371\/journal.pone.0031925","volume":"7","author":"G Rioux","year":"2012","unstructured":"Rioux G, Babin C, Majeau N, Leclerc D. Engineering of papaya mosaic virus (PapMV) nanoparticles through fusion of the HA11 peptide to several putative surface-exposed sites. PLoS ONE. 2012;7:e31925.","journal-title":"PLoS ONE"},{"key":"200_CR16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-3155-11-10","volume":"11","author":"C Babin","year":"2013","unstructured":"Babin C, Majeau N, Leclerc D. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP. J Nanobiotechnol. 2013;11:10.","journal-title":"J Nanobiotechnol"},{"key":"200_CR17","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1016\/j.vaccine.2008.04.052","volume":"26","author":"J Denis","year":"2008","unstructured":"Denis J, Acosta-Ramirez E, Zhao Y, Hamelin M-E, Koukavica I, Baz M, Abed Y, Savard C, Pare C, Lopez Macias C, Boivin G, Leclerc D. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine. 2008;26:3395\u2013403.","journal-title":"Vaccine"},{"key":"200_CR18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.virol.2007.01.011","volume":"363","author":"J Denis","year":"2007","unstructured":"Denis J, Majeau N, Acosta-Ramirez E, Savard C, Bedard M-C, Simard S, Lecours K, Bolduc M, Pare C, Willems B, Shoukry N, Tessier P, Lacasse P, Lamarre A, Lapointe R, Lopez Macias C, Leclerc D. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology. 2007;363:59\u201368.","journal-title":"Virology"},{"key":"200_CR19","doi-asserted-by":"crossref","first-page":"7245","DOI":"10.1016\/j.vaccine.2015.10.123","volume":"33","author":"D Carignan","year":"2015","unstructured":"Carignan D, Th\u00e9rien A, Rioux G, Paquet G, Gagn\u00e9 M\u00c8L, Bolduc M, Savard P, Leclerc D. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine. Vaccine. 2015;33:7245\u201353.","journal-title":"Vaccine"},{"key":"200_CR20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1477-3155-12-19","volume":"12","author":"G Rioux","year":"2014","unstructured":"Rioux G, Mathieu C, Russell A, Bolduc M, Lalibert\u00e9-Gagn\u00e9 ME, Savard P, Leclerc D. PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine. J Nanobiotechnol. 2014;12:19.","journal-title":"J Nanobiotechnol"},{"key":"200_CR21","doi-asserted-by":"crossref","first-page":"e21522","DOI":"10.1371\/journal.pone.0021522","volume":"6","author":"C Savard","year":"2011","unstructured":"Savard C, Gu\u00e9rin A, Drouin K, Bolduc M, Lalibert\u00e9-Gagn\u00e9 M-E, Dumas M-C, Majeau N, Leclerc D. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS ONE. 2011;6:e21522.","journal-title":"PLoS ONE"},{"key":"200_CR22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.nano.2013.02.009","volume":"9","author":"C Mathieu","year":"2013","unstructured":"Mathieu C, Rioux G, Dumas M-C, Leclerc D. Induction of innate immunity in lungs with virus-like nanoparticles leads to protection against influenza and Streptococcus pneumoniae challenge. Nanomedicine. 2013;9:839\u201348.","journal-title":"Nanomedicine"},{"key":"200_CR23","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.4049\/jimmunol.1302030","volume":"192","author":"M-\u00c8 Lebel","year":"2014","unstructured":"Lebel M-\u00c8, Daudelin J-F, Chartrand K, Tarrab E, Kalinke U, Savard P, Labrecque N, Leclerc D, Lamarre A. Nanoparticle adjuvant sensing by TLR7 enhances CD8+\u00a0T cell-mediated protection from Listeria monocytogenes infection. J Immunol. 2014;192:1071\u20138.","journal-title":"J Immunol"},{"key":"200_CR24","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1021\/acs.nanolett.5b04877","volume":"16","author":"M\u00c8 Lebel","year":"2016","unstructured":"Lebel M\u00c8, Chartrand K, Tarrab E, Savard P, Leclerc D, Lamarre A. Potentiating cancer immunotherapy using papaya mosaic virus-derived nanoparticles. Nano Lett. 2016;16:1826\u201332.","journal-title":"Nano Lett."},{"key":"200_CR25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ni.2511","volume":"14","author":"CG Vinuesa","year":"2013","unstructured":"Vinuesa CG, Chang P-P. Innate B cell helpers reveal novel types of antibody responses. Nat Immunol. 2013;14:119\u201326.","journal-title":"Nat Immunol"},{"key":"200_CR26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/156652407780059140","volume":"7","author":"GT Jennings","year":"2007","unstructured":"Jennings GT, Bachmann MF. Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med. 2007;7:143\u201355.","journal-title":"Curr Mol Med"},{"key":"200_CR27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/eji.1830260226","volume":"26","author":"KG Smith","year":"1996","unstructured":"Smith KG, Hewitson TD, Nossal GJ, Tarlinton DM. The phenotype and fate of the antibody-forming cells of the splenic foci. Eur J Immunol. 1996;26:444\u20138.","journal-title":"Eur J Immunol"},{"key":"200_CR28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/ni.1900","volume":"11","author":"CC Goodnow","year":"2010","unstructured":"Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R. Control systems and decision making for antibody production. Nat Immunol. 2010;11:681\u20138.","journal-title":"Nat Immunol"},{"key":"200_CR29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1126\/science.1183021","volume":"327","author":"A Iwasaki","year":"2010","unstructured":"Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291\u20135.","journal-title":"Science"},{"key":"200_CR30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cmi.2012.61","volume":"10","author":"Z Hua","year":"2013","unstructured":"Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol. 2013;10:103\u20136.","journal-title":"Cell Mol Immunol"},{"key":"200_CR31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","volume":"131","author":"B Pulendran","year":"2011","unstructured":"Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;131:509\u201317.","journal-title":"Nat Immunol"},{"key":"200_CR32","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1084\/jem.20120774","volume":"209","author":"CP Chappell","year":"2012","unstructured":"Chappell CP, Draves KE, Giltiay NV, Clark EA. Extrafollicular B cell activation by marginal zone dendritic cells drives T cell-dependent antibody responses. J Exp Med. 2012;209:1825\u201340.","journal-title":"J Exp Med"},{"key":"200_CR33","doi-asserted-by":"crossref","first-page":"E3224","DOI":"10.1073\/pnas.1323985111","volume":"111","author":"DC Rookhuizen","year":"2014","unstructured":"Rookhuizen DC, DeFranco AL. Toll-like receptor 9 signaling acts on multiple elements of the germinal center to enhance antibody responses. Proc Natl Acad Sci USA. 2014;111:E3224\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"200_CR34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09737","volume":"470","author":"SP Kasturi","year":"2011","unstructured":"Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, Garc\u00eda-Sastre A, Compans R, Pulendran B. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470:543\u20137.","journal-title":"Nature"},{"key":"200_CR35","doi-asserted-by":"crossref","first-page":"e78947","DOI":"10.1371\/journal.pone.0078947","volume":"8","author":"A Jegerlehner","year":"2013","unstructured":"Jegerlehner A, Zabel F, Langer A, Dietmeier K, Jennings GT, Saudan P, Bachmann MF. Bacterially produced recombinant influenza vaccines based on virus-like particles. PLoS ONE. 2013;8:e78947.","journal-title":"PLoS ONE"},{"key":"200_CR36","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.vaccine.2012.01.085","volume":"30","author":"C Savard","year":"2012","unstructured":"Savard C, Lalibert\u00e9-Gagn\u00e9 M-\u00c8, Babin C, Bolduc M, Gu\u00e9rin A, Drouin K, Forget M, Majeau N, Lapointe R, Leclerc D. Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP]. Vaccine. 2012;30:2535\u201342.","journal-title":"Vaccine"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-016-0200-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T09:32:17Z","timestamp":1568021537000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-016-0200-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,10]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1186\/s12951-016-0200-2","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,10]]},"article-number":"43"}}